Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antivir Ther
    October 2026
  1. SHEN Y, Huang EY, Yin O, Shiau S, et al
    Kidney function parameters in South African children living with HIV on antiretroviral therapy.
    Antivir Ther. 2026;31:13596535261490958.
    >> Share

    August 2026
  2. PENNETZDORFER N, Naik V, Montezuma-Rusca JM, Sklar P, et al
    Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.
    Antivir Ther. 2026;31:13596535261481194.
    >> Share

    June 2026
  3. PANNECOUCKE C, Valin N, Peytavin G, Lambert S, et al
    Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.
    Antivir Ther. 2026;31:13596535261436877.
    >> Share

  4. EFRIDA, Yuza A
    Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.
    Antivir Ther. 2026;31:13596535261450699.
    >> Share

    April 2026
  5. YOUNG J, Lawler PR, Moodie EEM, Bucher HC, et al
    It's about time: The association between abacavir and cardiovascular disease.
    Antivir Ther. 2026;31:13596535261438178.
    >> Share

    October 2025
  6. DE KOFF EM, van Andel H, de Jong HK, van der Kooi AJ, et al
    Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
    Antivir Ther. 2025;30:13596535251385624.
    >> Share

    June 2025
  7. GAO Y, Ji W, Chen Q
    The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis.
    Antivir Ther. 2025;30:13596535251345870.
    >> Share

  8. VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al
    Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1.
    Antivir Ther. 2025;30:13596535251349336.
    >> Share

    April 2025
  9. ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al
    Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort study.
    Antivir Ther. 2025;30:13596535251333259.
    >> Share

  10. PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al
    Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.
    Antivir Ther. 2025;30:13596535251335080.
    >> Share

  11. LABATE L, Rossetti B, Russo C, Cassol C, et al
    Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
    Antivir Ther. 2025;30:13596535251317054.
    >> Share

    February 2025
  12. PICKERING RT, Asundi A, Olson A, Soden K, et al
    Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
    Antivir Ther. 2025;30:13596535251314571.
    >> Share

    December 2024
  13. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
    Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
    Antivir Ther. 2024;29:13596535241306467.
    >> Share

    April 2024
  14. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
    Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
    Antivir Ther. 2024;29:13596535241248282.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016